Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-30
2011-11-22
Morris, Patricia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S273700
Reexamination Certificate
active
08063074
ABSTRACT:
Polymorphic crystalline Forms J, K, L, M, and N of esomeprazole sodium.
REFERENCES:
patent: 5693818 (1997-12-01), Von Unge
patent: 5948789 (1999-09-01), Larsson et al.
patent: 6143771 (2000-11-01), Lindberg
patent: 6627646 (2003-09-01), Bakale et al.
patent: 6875872 (2005-04-01), Lindberg
patent: 2005/0031696 (2005-02-01), Kolbe
patent: 1 020 460 (2000-07-01), None
patent: WO 98/54171 (1998-12-01), None
patent: WO03/089408 (2003-10-01), None
patent: WO 2004/020436 (2004-03-01), None
patent: WO 2004/046134 (2004-06-01), None
patent: WO 2004/089935 (2004-10-01), None
patent: WO 2005/054228 (2005-06-01), None
patent: WO 2006/001753 (2006-01-01), None
patent: WO 2006/001755 (2006-01-01), None
Chemical & Engineering News, Feb. 2003, 32-35.
Brittain ed., “Polymorphism, etc.,” NY:Marcel Dekker, Inc., 1999, 1-2, 183-226, 235-238.
U.S. Pharmacopia #23, National Formulary #18, 1995, 1843-1844.
Muzaffar et al., “Polymorphism and Drug Availability, etc.,” J of Pharm. (Lahore), 1979, 1(1), 59-66.
Jain et al., “Polymorphism in Pharmacy”, Indian Drugs, 1986, 23(6) 315-329.
Taday et al., “Using Terahertz, etc.,” J of Pharm. Sci., 92(4), 2003, 831-838.
Concise Encyclopedia Chemistry, NY: Walter de Gruyter, 1993, 872-873.
Rowland & Tozer, “Clinical Pharmacokinetics, etc.,” 1995, p. 123.
Silverman, The Organic Chemistry of Drug Design and Drug Action, NY: Academic Press, 1993, 72-76.
Ulicky. Comprehensive Dictionary of Physical Chemistry, NY: Prentice Hall, 1992, p. 21.
Doelker, english translation of Ann. Pharm. Fr., 2002, 60: 161-176, pp. 1-39.
Doelker, english translation of S.T.P, Pratiques (1999), 9(5), 399-409, pp. 1033.
Otuska et al., “Effect of Polymorphic, etc.,” Chem. Pharm. Bull., 47(6) 852-856 (1999).
Cmu Pharmaceutical polymorphism, internet, p. 1-3 (2002) (print out Apr. 3, 2008).
Singhal et al., “Drug Polymorphism, etc.,” Advanced Drug Delivery reviews 56, p. 335-347 (2004).
Caira, “Crystalline Polymorphism, etc.,” Topics in Current Chemistry, 198, 163-208 (1998).
Bernstein et al., “Polymorphism in Molecular Crystals”, Oxford: Clarendon Press, 2002, pp. 117, 118 and 272.
Davidovitch et al., “Dectection of Polymorphism, etc.,” American Pharmaceutical Review, In: Russell Pub., 2004, 7(1), pp. 10, 12, 14, 16 and 100.
Gavezzotti, Angelo, “Are Crystal Structures Predictable?”, Acc. Chem. Res., 1994, 27, 309-314.
Gavezzotti, Angelo, “Ten years of experience in polymorph prediction: what next?”, CrystEngComm, 2002, 4(61), 343-347.
Singhal, Dharmendra, “Drug polymorphism and dosage form design: a practical perspective,” 2004, 56, 335-347.
Day, Graeme M., et al., (2006) “Investigating the latent polymorphism of maleic acid,” Chemical Communications 1 (1): 54-56.
Thallapally, Praveen K., (2004) “Polymorphism of 1,3,5-Trinitrobenzene Induced by a Trisindane Additive,” Angewandte Chemie International Edition, 43 (9): 1149-1155.
Bolugoddu Vijayabhaskar
Cheemalapati Venkata Annapurna Sasikala
Chitre Saurabh Shashikant
Lekkala Amarnath Reddy
Mamilla Srinivas Reddy
Dr. Reddy's Laboratories Inc.
Dr. Reddy's Laboratories Limited
Franks Robert A.
Gupta Balaram
McKenzie Thomas C.
LandOfFree
Polymorphic forms of esomeprazole sodium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphic forms of esomeprazole sodium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic forms of esomeprazole sodium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272068